Rasmussen, Lars by unknown
Syddansk Universitet
18F-DOPA PET/CT and 68Ga-DOTANOC PET/CT scans as diagnostic tools in focal
congenital hyperinsulinism
a blinded evaluation
Dahl Christiansen, Charlotte; Petersen, Henrik ; Nielsen, Anne Lerberg; Detlefsen, Sönke;
Brusgaard, Klaus; Rasmussen, Lars; Melikyan, Maria; Ekström, Klas; Globa, Evgenia;
Rasmussen, Annett Helleskov; Hovendal, Claus; Thybo Christesen, Henrik
Published in:
European Journal of Nuclear Medicine and Molecular Imaging
DOI:
10.1007/s00259-017-3867-1
Publication date:
2018
Document version
Publisher's PDF, also known as Version of record
Document license
CC BY
Citation for pulished version (APA):
Christiansen, C. D., Petersen, H., Nielsen, A. L., Detlefsen, S., Brusgaard, K., Rasmussen, L., ... Christesen, H.
T. (2018). 18F-DOPA PET/CT and 68Ga-DOTANOC PET/CT scans as diagnostic tools in focal congenital
hyperinsulinism: a blinded evaluation. European Journal of Nuclear Medicine and Molecular Imaging, 45(2),
250–261. DOI: 10.1007/s00259-017-3867-1
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 09. sep.. 2018
ORIGINAL ARTICLE
18F-DOPA PET/CT and 68Ga-DOTANOC PET/CT scans
as diagnostic tools in focal congenital hyperinsulinism:
a blinded evaluation
Charlotte Dahl Christiansen1,2 & Henrik Petersen3 & Anne Lerberg Nielsen3 &
Sönke Detlefsen2,4 & Klaus Brusgaard5 & Lars Rasmussen6 & Maria Melikyan7 &
Klas Ekström8 & Evgenia Globa9 & Annett Helleskov Rasmussen1,2 & Claus Hovendal6 &
Henrik Thybo Christesen1,2,10,11
Received: 26 June 2017 /Accepted: 20 October 2017 /Published online: 8 November 2017
# The Author(s) 2017. This article is an open access publication
Abstract
Purpose Focal congenital hyperinsulinism (CHI) is curable
by surgery, which is why identification of the focal lesion is
crucial. We aimed to determine the use of 18F–fluoro-
dihydroxyphenylalanine (18F-DOPA) PET/CT vs. 68Ga-
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic-acid-1-
Nal3-octreotide (68Ga-DOTANOC) PET/CT as diagnostic
tools in focal CHI.
Methods PET/CT scans of children with CHI admitted to
Odense University Hospital between August 2005 and
June 2016 were retrospectively evaluated visually and by their
maximal standardized uptake values (SUVmax) by two inde-
pendent examiners, blinded for clinical, surgical and patho-
logical data. Pancreatic histology was used as the gold stan-
dard. For patients without surgery, the genetic profile served
as the gold standard.
Results Fifty-five CHI patients were examined by PET/CT
(18F-DOPA n = 53, 68Ga-DOTANOC n = 18). Surgery was
performed in 34 patients, no surgery in 21 patients. Fifty-one
patients had a classifiable outcome, either by histology
(n = 33, 22 focal lesions, 11 non-focal) or by genetics
(n = 18, all non-focal). The predictive performance of 18F-
DOPA PET/CT to identify focal CHI was identical by visual-
and cut-off-based evaluation: sensitivity (95% CI) of 1 (0.85–
1); specificity of 0.96 (0.82–0.99). The optimal 18F-DOPA
PET SUVmax ratio cut-off was 1.44 and the optimal 68Ga-
DOTANOC PET SUVmax cut-off was 6.77 g/ml. The area
under the receiver operating curve was 0.98 (0.93–1) for
18F-DOPA PET vs. 0.71 (0.43–0.95) for 68Ga-DOTANOC
PET (p < 0.03). In patients subjected to surgery, localization of
the focal lesion was correct in 91%, and 100%, by 18F-DOPA
PET/CT and 68Ga-DOTANOC PET/CT, respectively.
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Conclusion 18F-DOPA PET/CT was excellent in predicting
focal CHI and superior compared to 68Ga-DOTANOC PET/
CT. Further use of 68GA-DOTANOC PET/CT in predicting
focal CHI is discouraged.
Keywords Congenital hyperinsulinism . Hypoglycaemia .
Positron emission tomography . Endocrine pancreas . Genetic
diseases
Introduction
Congenital hyperinsulinism (CHI) is a rare, heterogeneous
disease characterized by inappropriate insulin secretion from
pancreatic islet β-cells resulting in hypoglycaemia [1]. The
approximate incidence of persistent CHI is 1/40,000 live
births in countries without founder mutations [2, 3]. The ele-
vated serum insulin results in hypoketotic hypoglycaemia and
a clinical presentation ranging from weak symptoms to loss of
consciousness and seizures with a high risk of brain damage
[1, 4].
The twomajor histological forms of CHI are the focal and the
diffuse forms. Focal CHI occurs in 40–50% of cases [5] and is
defined as a restricted pancreatic area with adenomatous β-cell
hyperplasia, resulting in a lesion composed of confluent islets of
Langerhans [6, 7]. Diffuse CHI involves the islets of Langerhans
throughout the pancreas and is histologically characterized by
hypertrophy of a few β-cell nuclei in most islets of
Langerhans. In 50–66% of patients with diffuse CHI, mutations
are found in the KATP-channel genes ABCC8 orKCNJ11, coding
for the sulphonylurea receptor 1 (SUR1) and the potassium in-
ward rectifier 6.2 (Kir6.2), respectively [6, 8]. Recessive
inactivating mutations in ABCC8/KCNJ11 are the most common
causes of medically unresponsive diffuse CHI [9], whereas dom-
inantly inherited ABCC8/KCNJ11 mutations typically are medi-
cally responsive [1].
Focal CHI is strongly associated with a heterozygous, pater-
nally inherited KATP-channel germline mutation, as this com-
bined with a somatic loss of heterozygosity in chromosome
11p15 in a focal region of the pancreas results in hemizygosity
of the paternal ABCC8/KCNJ11mutation and loss of maternally
expressed tumor suppressors [1].
The primary treatment goal is to increase and maintain
blood glucose concentration above at least 3.5 mmol/L to
avoid brain damage [10]. The treatment modalities include
diet, i.v. glucose infusion, anti-insulin medical therapy (pri-
marily diazoxide and octreotide) and pancreatic surgery [1].
Focal CHI is curable after a focal enucleation, or partial pan-
createctomy, without subsequent risk of diabetes or malab-
sorption [9, 11]. Surgery for diffuse CHI should be restricted
to medical non-responders and ranges from partial to subtotal
pancreatectomy; the first is most often ineffective, and the
latter imposes a high risk of diabetes mellitus and exocrine
pancreatic insufficiency [11, 12].
Today, 18F–fluoro-dihydroxyphenylalanine (18F-DOPA)
PET is the preferred tool in discerning focal from non-focal
CHI [13]. L-DOPA is converted to dopamine by the aromatic
amino acid decarboxylase enzyme in neuroendocrine cells
[14]. The combined use of 18F-DOPA PET and CT [15–19]
or MRI [20, 21] allows for a precise localization of the focal
process prior to surgery. The preoperative identification of a
focal lesion can be made by visual [15, 16, 18, 21] or quanti-
tative [17, 19, 20, 22] methods. By the quantitative approach,
a high standardized uptake value (SUV) ratio is used to iden-
tify the focal lesion. However, published diagnostic SUVratio
cut-offs range from 1.2 [22] to 1.5 [17, 19, 20]. 18F-DOPA is
not available in every country and is more difficult to manu-
f a c t u r e t h a n a n o t h e r t r a c e r , 6 8G a - 1 , 4 , 7 , 1 0 -
tetraazacyclododecane-1,4,7,10-tetraacetic acid-1-Nal3-
octreotide (68Ga-DOTANOC). 68Ga-DOTANOC is a so-
matostatin analogue radiotracer with high affinity to the so-
matostatin receptor (SSTR) subtypes 2, 3, and 5. All the SSTR
subtypes are variably expressed in endocrine cells of the islets
of Langerhans [23], but the diagnostic value of 68Ga-
DOTANOC PET/CT in the diagnosis of focal CHI is un-
known [24]. As the waiting time to expert treatment is essen-
tial for the cerebral prognosis [4], a more easily available
alternative to the 18F-DOPA PETwould be desirable to short-
en time to curative surgery for focal CHI patients born far
from these centers.
We aimed to evaluate 18F-DOPA PET/CT and 68Ga-
DOTANOC PET/CT as diagnostics tools in focal CHI preop-
eratively, analyzed visually or quantitatively, by ratio of max-
imal SUV values (SUVmax ratio) for 18F-DOPA PET/CT, or
SUVmax for 68Ga-DOTANOC PET/CT.
Patients and methods
We retrospectively investigated children with CHI admitted to
the International Hyperinsulinism Center at Odense
University Hospital, Denmark, between August 2005 and
June 2016, subjected to 18F-DOPA PET/CT and/or 68Ga-
DOTANOC PET/CT scan.
The CHI diagnosis was based on an inappropriately elevated
p-insulin concentration during hypoglycaemia. Patients above
18 years were excluded, leading to final inclusion of 55 patients.
Anti-insulin medication was stopped two days prior to the
PET/CT scan, allowing verification of the diagnosis of persis-
tent CHI and evaluation of disease severity. To minimize
stress for the patients and movement artifacts, 18F–DOPA
PET/CT scans were obtained under general anesthesia (60-
min acquisition time), while most 68Ga-DOTANOC PET/
CT scans were performed under sedation (5-min acquisition
time).
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PET/CT-based assessment
PET/CTscans were acquired on a GE Discovery PET/CTscan-
ner (GE Medical System, Waukesha, WI, USA) and analyzed
on a Dexus AW server 2.0. 18F–DOPA was produced by the
electrophilic method. The patients were injected with 18F–
DOPA or 68Ga-DOTANOC 4 MBq/kg, minimum 30 MBq.
One field of view (FOV; acquisition time 5 min/FOV) was
obtained over the pancreatic region at 10, 30 and 60 min.
After injection, 68Ga-DOTANOC scans were obtained at 10,
30 and 60 min (n = 6), or at 30 min (n = 1), 45 min (n = 8) or
60 min (n = 3). A low-dose CT scan was performed prior to the
first scan to be used for attenuation correction; acquisition pa-
rameters were 80–100 kV, 30–40 mA, rotation 0.8 s and pitch
0.984:1. A contrast-enhanced diagnostic CT scan over the pan-
creatic region was performed afterwards in all but one patient
with suspicion of focal CHI to aid surgeons to localize the focal
lesion: acquisition parameters were 120 kV, 30–400 mA,
SmartmA, rotation 0,8 s, pitch 0.984:1 and noise index of 10.
The CT scans were iteratively reconstructed to minimize radia-
tion dose. Diagnostic CT scans were evaluated by radiologists.
PET/CT scans were anonymized and case numbers of 18F–
DOPA, and 68Ga-DOTANOC scans were randomized indepen-
dently from each other. SUVmax values were measured in g/ml
and the region of interest (ROI) was shaped as a sphere. Results
of the attenuation-corrected 18F–DOPA and 68Ga-DOTANOC
PET/CTwere evaluated by two independent researchers (C.D.C
and A.L.N), blinded for all other clinical, radiological, surgical
and pathological data. Disagreement was defined as a difference
in SUVmax > 10%, a SUV ratio difference > 0.2 or a difference
in visual or quantitative conclusion; the latter applied for 18F–
DOPA PET based on a predefined SUV ratio cut-off = 1.45.
Disagreements were resolved by a third party (H.P.). Two pa-
tients enrolled in the study were evaluated by A.T and M.H.V
(see Acknowledgements) due to blinding issues, and disagree-
ment was resolved by a third party (H.P).
The PET/CT scans were evaluated in the following order:
1) Visual method: a visually higher uptake of radiotracer in a
part of the pancreas was considered positive for a focal pro-
cess, and locationwas noted. A uniform uptake throughout the
pancreas was considered diffuse. 2) Measurement of the
SUVmax ratio in the pancreas: SUVmax in the part of the pan-
creas that visually appeared to be abnormal, divided by
SUVmax in the part of the pancreas that visually appeared to
be homogenous and normal (body or head). The SUVmax ratio
was measured at 10, 30 and 60min after injection. The highest
SUVmax ratio was used and location was noted.
Patient files were evaluated after the blinded PET/CT eval-
uation. The following data were extracted from the medical
records; sex, age at disease onset and at admission, country of
origin, family history, genetic analyses, medication, maximal
intravenous glucose infusion rate (off-medication prior to
PET/CT scan) and lowest recorded blood glucose
concentration. Insulin, proinsulin and C-peptide concentra-
tions were obtained during hypoglycaemia, defined as a blood
glucose below 2.5 mmol/L (neonatal period), or below
3.2 mmol/L (thereafter). The location and size of the lesions,
results of frozen section microscopy and the final histological
diagnoses were retrieved from the pathology report.
Histopathological analysis
The histological diagnoses were retrieved from the files of the
Dept. of Pathology, Odense University Hospital, Denmark, in
all cases with surgery, except two patients who were operated
upon abroad. For the final histological diagnoses, the pathol-
ogy protocol for formalin-fixed, paraffin-embedded pancreat-
ic tissue included hematoxylin-eosin of 4-μm-thick sections;
immunohistochemical staining using the BenchMark Ultra
immunostainer (Ventana Medical Systems, Tucson, AZ,
USA) with the OptiView-DAB detection kit (Ventana
Medical Systems, Tucson, AZ, USA); nuclear counterstaining
with the BenchMark Ultra instrument using Hematoxylin II
(Ventana Medical Systems, Tucson, AZ, USA), and
coverslipping using a Tissue-Tek Film coverslipper (Sakura,
Alphen aan den Rijn, The Netherlands). In most cases, immu-
nohistochemical examination included synaptophysin,
chromogranin A, insulin, glucagon, somatostatin, and the ma-
ternally expressed tumor suppressor p57. For preoperative
frozen section analysis, 4-μm-thick frozen sections were
stained with hematoxylin-eosin and tolouidin blue. Besides,
particularly when the tissue specimens submitted for frozen
section were small (< 5 mm), manual immunohistochemical
staining of frozen sections for synaptophysin and insulin was
performed.
Genetic analysis
Prior to 2007, genetic analyses were performed by de-
naturing high-pressure liquid chromatography (dHPLC)
analysis of ABCC8 and KCNJ11 as previously described
[25]. A positive dHPLC was followed by Sanger se-
quencing [26]. From 2007 to 2013, analysis of
ABCC8, KCNJ11, GLUD1, GCK, HNF1-alfa and
HNF4-alfa was performed using Sanger sequencing
[26]; from 2011, also including HNF1-beta, and from
2012, also including HADH, MCT1 and UCP2. From
2013 and onwards, analysis of the before-mentioned
genes was performed using next-generation sequencing
(NGS) as previously described [27] followed by Sanger
sequencing for confirmation of mutations found by
NGS. Pathogenicity analyses were performed using mul-
tiple software programs [28–34]. Only previously report-
ed mutations or rare DNA variants predicted by
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software analysis to be disease-causing were accepted as
pathogenic.
Statistics
Continuous variables were expressed by the median and in-
terquartile ranges (IQR); categorical data in number and per-
centage. To estimate reproducibility, kappa values were calcu-
lated for categorical variables and intraclass correlation coef-
ficients (ICC) for numerical variables. Reproducibility tests
were made between patients analyzed by C.D.C and A.L.N.
Histopathology after surgery was used as the primary
gold standard to discern focal from non-focal (diffuse or
atypical) CHI. In patients not subjected to surgery, the
absence of a heterozygous, paternal ABCC8/KCNJ11
mutation was used as a secondary gold standard for
non-focal CHI (no patients showed evidence of a dom-
inant, paternal ABCC8/KCNJ11 mutation). If no gold
standard was available, the patient was excluded from
analyses of test performance.
The performance of the PET/CT scans was tested on both
the combined gold standard outcome (surgical and non-
surgical patients) and on the primary gold standard outcome
(histologically confirmed focal lesion after surgery).
To investigate test performance, receiver operating curves
(ROC) were drawn from the SUVmax ratio (18F–DOPA PET)
and the SUVmax (68Ga-DOTANOC PET). The optimal cut-
off to maximize accuracy, the area under the curve (AUC) and
the corresponding 95% CI were calculated by a bootstrap of
10,000.
Sensitivity, specificity, positive and negative predic-
tive values (PPV and NPV, respectively) were calculated
for the visual, or SUV-based, diagnostic prediction of
focal CHI, including for the SUV ratio cut-off of 1.44
[21]. The 95% CIs were calculated by the Wilson meth-
od [35]. Comparison of SUVmax ratios and SUVmax
values between groups was done using Mann–Whitney
U tests. Comparison of PET/CT scan test performances
was done by their 95% CI [36]. Comparison of superi-
ority of ROC AUC of 18F–DOPA PET over 68Ga-
DOTANOC PET was done using a non-paired bootstrap
of 10,000.
Disease severity expressed as lowest blood glucose, or
maximal glucose infusion demand without medication prior
to PET/CT scan, was compared to the SUVmax ratio of 18F–
DOPA PET in focal CHI by a linear model. In addition, the
SUVmax ratio of the verified focal lesions were correlated to
serum concentrations of insulin, proinsulin and C-peptide, and
to the insulin-to-glucose ratio. Corresponding p values were
calculated by t tests.
All data analyses were performed using the statistical soft-
ware program R, version 3.1.2 [37], including several
packages [38–44]. Level of significance was p < 0.05, trends
0.05–0.10.
Results
Of the 55 children with CHI, 53 had a PET/CT scan
with 18F–DOPA, and 18 had a 68Ga-DOTANOC scan,
of which 16 also had an 18F–DOPA scan (Table 1).
The median (IQR) age at PET/CT scan was 7 (3.5–
18.5) months. Among patients who underwent surgery
(n = 34), pathology reports showed focal CHI in 22
(64.7%), diffuse CHI in 10 (29.4%), atypical CHI in
one (2.9%) and normal pancreatic histology in the ana-
lyzed tissue in one (2.9%; Table 2). The patients with
non-focal CHI who underwent surgery were unrespon-
sive to medication with high risk of (further) brain dam-
age from hypoglycaemia. The operated upon patient
with normal pancreatic tail histology and three patients
without surgery had mutations of uncertain pathogenic-
ity and were excluded from analyses of test performance
and ROC.
Examples of 18F–DOPA PET/CT and 68Ga-DOTANOC
PET/CT are shown in Fig. 1.
The kappa value for the visual evaluation of the 51
18F–DOPA PET/CT scans was 0.74 (95% CI 0.55–0.93)
and 0.89 (0.68–1) for the 18 68Ga-DOTANOC PET/CT.
The ICC of the SUVmax ratio values of the 18F–DOPA
PET scans was 0.96 (0.94–0.98). For 68Ga-DOTANOC
PET, the ICC of the SUVmax values was 0.95 (0.88–
0.98). Additional ICC values for 68Ga-DOTANOC
PET are shown in Online Resource Table 1.
Evaluation of 18F–DOPA PET/CT
Visual evaluation of 18F–DOPA PET/CT showed a sen-
sitivity of 1 (0.85–1), specificity of 0.96 (0.82–0.99), a
PPV of 0.96 (0.79–0.99) and an NPV of 1 (0.87–1) for
the prediction of focal CHI (Table 3a). Equivalent re-
sults were obtained when only histology was used as
the isolated gold standard (Table 3b). Tracer uptake in
the gall bladder and common bile duct was seen once at
the 10-min series and more frequently at 30 or 60 min.
The variable staining allowed discrimination of common
bile duct staining from suspected focal lesion.
The maximal tracer values by 18F–DOPA PET were
obtained at 10 min in 12 patients (focal n = 4), at
30 min in 13 patients (focal n = 5) and at 60 min in
24 patients (focal n = 13). SUVmax ratio values of the
focal lesions had a median (IQR) of 1.72 (1.58–2.27),
ranging from 1.47 to 4.69, compared to 1.12 (1.05–
1.20), with a range of 0.94–1.73, for the non-focal type
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(p < 0.0001). The classified non-focal patient with an
SUVmax ratio of 1.73 was not subjected to surgery and
had a normal ABCC8/KCNJ11 genetic analysis, which
may represent a false negative genotype for focal CHI.
The performance of 18F–DOPA PETwas excellent with an
ROC AUC of 0.98 (0.93–1; Fig. 2a). The optimal SUVmax
ratio cut-off was 1.44 (1.35–1.46). Equivalent results were
obtained when using histology as the isolated gold standard
(Fig. 2c).
Quantitative evaluation of 18F–DOPA PET using the cut-
off of 1.44 showed the exact same estimates for test perfor-
mance as the visual evaluation (Table 3).
Table 1 Patient characteristics
Patients
Country of origin, no. (%)
Belarus 2 (3.6)
Denmark and Greenland 13 (23.6)
Kazakhstan 3 (5.5)
Latvia 2 (3.6)
Norway 1 (1.8)
Russia 15 (27.3)
Sweden 10 (18.2)
Syria 1 (1.8)
Ukraine 7 (12.7)
United Kingdom 1 (1.8)
Sex
Female (%) 25 (45.5)
Male (%) 30 (54.5)
Age at diagnosis (month), median (IQR)a, no. = 54 0 (0–0)
Age at PET/CT (month), median (IQR), no. = 55 7 (3.5–18.5)
Surgery, no. (%) 34 (61.8)
Disease severity, median (IQR)
Lowest blood glucose (mmol/L), no. = 55 1.0 (0.6–1.6)
Glucose demandb (mg/kg/min), no. = 51 8.5 (4.4–12.1)
P-insulin during hypoglycaemia (pmol/L)d, no. = 37 90 (48–115)
Insulin-to-glucose ratioc (pmol/mmol) no. = 37 38.4 (18.1–55.6)
Genetic mutations, no. (%)
ABCC8 34 (61.8)
Paternal 22
Maternal 1
Compound heterozygous 8
Homozygous 1
De novo 2
KCNJ11 4 (7.3)
Paternal 3
Maternal 1
GLUD1 1 (1.8)
UPD11 1 (1.8)
HNF4-alfa 1 (1.8)
No disease-causing mutations found 14 (25.5)
a Range: 0–9 months
bMedication-free
c Obtained during hypoglycaemia (glucose <2.5 mmol/L for age < 3 days, glucose <3.2 mmol/l for age ≥ 3 days)
d P-insulin at low p-glucose, reference <18 pmol/L
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Evaluation of 68Ga-DOTANOC PET/CT
Visual evaluation of 68Ga-DOTANOC PET/CT showed
a test performance with a sensitivity of 0.78 (0.45–
0.94), a specificity of 0.86 (0.49–0.97), a PPV at 0.88
(0.53–0.98) and an NPV at 0.75 (0.41–0.93). Equivalent
results were obtained when histology was used as the
isolated gold standard (Table 3).
The maximal tracer values by 68Ga-DOTANOC PETwere
obtained in 30–60min (zero patients at 10 min, two patients at
30 min; focal n = 1), seven patients at 45 min (focal n = 3) and
seven patients at 60 min (focal n = 5). SUVmax values of the
focal lesions had a median (IQR) of 9.43 (5.86–12.51) with a
range of 2.32–16.81 g/ml, compared to 4.71 (3.27–6.98) with
a range 2.31–13.42 g/ml for the non-focal type (p = 0.17).
The diagnostic performance of SUVmax in 68Ga-
DOTANOC PET was fair with an ROC AUC of 0.71 (0.43–
0.95; Fig. 2b). The optimal SUVmax cut-off was 6.77 (3.47–
9.90) g/ml. Test performance showed a sensitivity of 0.67
(0.35–0.88), a specificity of 0.71 (0.36–0.92), a PPV of 0.75
(0.41–0.93) and an NPV of 0.63 (0.31–0.86). No significant
difference was obtained if applying histology only as the gold
standard (Fig. 2d, Table 3).
Differences between point estimates of the visual analysis
vs. SUVmax cut-offs by 68Ga-DOTANOC PET did not reach
significance.
DOPA vs. DOTANOC scans
The ROC AUC of 18F–DOPA PETshowed a superior perfor-
mance compared to 68Ga-DOTANOC PET; p = 0.025 (his-
tology and genetic analysis as the gold standard), and
p = 0.017 (histology only as the gold standard).
The 18F–DOPA PET/CT (by visual or SUV ratio) detected
the correct location in 91% (20/22) of the cases with focal
lesions. Two lesions were incorrectly located. The first patient
with an incorrectly located focal lesion (from 2007, no sup-
plementary 68Ga-DOTANOCPETscan and no diagnostic CT
scan) was deemed to be located in the head of the pancreas;
the lesion was later identified at the tip of the pancreatic tail.
The second patient (from 2016, no supplementary 68Ga-
DOTANOC PETscan) had an ectopic lesion in the duodenum
near the major duodenal papilla. The lesion was horseshoe-
shaped and extended into the pancreas. The pancreatic part of
the lesion was correctly located by the PET/CT but the true
nature of the lesion was classified by histology.
The 68Ga-DOTANOC PET/CT (visual and SUVmax) scans
detected the correct location in 7/7 and 6/6 of the cases.
68Ga-DOTANOC PET SUVmax ratios
In a post-hoc analysis of 68Ga-DOTANOC PET, we
attempted calculating SUVmax ratios by use of normal pancre-
atic tissue, spleen or liver as reference. The resulting ROC
curve and test values were not significantly different from
the use of pancreatic SUVmax. Data are given in Online
Resource Table 2 and Online Resource Fig. 1.
Disease severity and SUVmax ratio
No relationship was observed between the minimal blood glu-
cose, or maximal glucose infusion demand, and the 18F–
DOPA PET SUVmax ratio of a focal lesion (p = 0.88 and
p = 0.39, respectively; Fig. 3a–b). Equivalent results were
obtained when analyzing serum insulin, C-peptide, proinsulin
and insulin-to-glucose ratios (Fig. 3c–f).
Discussion
In this blinded retrospective study, we found significantly bet-
ter performance of 18F–DOPA PET/CT compared to 68Ga-
DOTANOC PET/CT in preoperative prediction of focal CHI.
Table 2 Gold standard for type of CHI
Number (%)
All patients 55
Included patients 51 (92.7)
Histology (after surgery): n = 33
Focal 22 (64.7)
Non-focal
Diffuse 10 (29.4)
Atypical 1 (2.9)
Genetics (no. surgery): n = 18
Suspected focala 0 (0)
Suspected non-focal 18 (85.7)
ABCC8: maternal, heterozygous 1
ABCC8: compound heterozygous 1
ABCC8: homozygous 1
GLUD1: heterozygous 1
HNF4-alfa: heterozygous 1
No mutations found 13
Excluded patients 4 (7.3)
Normal histology report 1 (2.9)
Genetic variants of uncertain pathogenicity 3 (14.3)
ABCC8: paternal 1
ABCC8:de novo 1
KCNJ11: maternal 1
a Heterozygous paternal ABCC8/KCNJ11 mutation
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For 18F–DOPA PET/CT, the visual criteria performed identi-
cally excellent as compared with an optimal SUVmax ratio cut-
off of 1.44 after ROC curve evaluation. Clinical disease se-
verity did not correlate with the size of the SUVmax ratio.
Only a few case reports have been published regarding the
use of 68Ga-DOTANOC in the prediction of focal CHI, and
with variable success [24, 45]. The wider availability of 68Ga-
DOTANOC could argue for the use of this tracer, but the need
of a systematic evaluation of the performance of 68Ga-
DOTANOC has not been met until now.
Our optimal SUVmax ratio cut-off in 18F–DOPA PET to
predict focal CHI was 1.44. To the best of our knowledge, this
is the first attempt to classify an SUVmax ratio cut-off in CHI
by the use of the ROC. Others have advocated a cut-off ratio
Table 3 Test performance of 18F–DOPA PET/CT and 68GA-DOTANOC PET/CT in predicting focal CHI
Method No. Sensitivity (95% CI) Specificity (95% CI) PPV (95% CI) NPV (95% CI) Locationa (%)
a) Patients with histology or genetics as gold standard
18F–DOPA PET visual 49 1 (0.85–1) 0.96 (0.82–0.99) 0.96 (0.79–0.99) 1 (0.87–1) 20/22 (91)
18F–DOPA PET cut-off 1.44 49 1 (0.85–1) 0.96 (0.82–0.99) 0.96 (0.79–0.99) 1 (0.87–1) 20/22 (91)
68Ga-DOTANOC PET visual 16 0.78 (0.45–0.94) 0.86 (0.49–0.97) 0.88 (0.53–0.98) 0.75 (0.41–0.93) 7/7 (100)
68Ga-DOTANOC PET cut-off 6.77 16 0.67 (0.35–0.88) 0.71 (0.36–0.92) 0.75 (0.41–0.93) 0.63 (0.31–0.86) 6/6 (100)
b) Patients with histology as gold standard
18F–DOPA PET visual 32 1 (0.85–1) 1 (0.72–1) 1 (0.85–1) 1 (0.72–1) 20/22 (91)
18F–DOPA PET cut-off 1.44 32 1 (0.85–1) 1 (0.72–1) 1 (0.85–1) 1 (0.72–1) 20/22 (91)
68Ga-DOTANOC PET visual 14 0.78 (0.45–0.94) 0.80 (0.38–0.96) 0.88 (0.53–0.98) 0.67 (0.30–0.90) 7/7 (100)
68Ga-DOTANOC PET cut-off 7.73 14 0.56 (0.27–0.81) 0.60 (0.23–0.88) 0.71 (0.36–0.92) 0.43 (0.16–0.75) 5/5 (100)
a Correctly located/correct focal identification according to histology after surgery
PPV, positive predictive value, NPV, negative predictive value
Fig. 1 18F–DOPA PET/CT and 68Ga-DOTANOC PET/CT performed
in three patients. a–d Patient 1, focal CHI. e–h Patient 2, focal CHI. i–l
Patient 3, diffuse CHI. Column I shows 18F–DOPA PET; column II 18F–
DOPA PET/CT (here contrast-enhanced); column III 68Ga-DOTANOC
PET/CT; column IV 68Ga-DOTANOC PET. Red arrows point to the
focal lesions. In the blinded evaluations, patient 1 and 2 were correctly
diagnosed as focal and patient 3 as non-focal CHI by 18F–DOPA PET/
CT (visual and by cut-off method). By 68Ga-DOTANOC PET/CT, pa-
tient 1 and patient 3 were correctly classified, but patient 2 was wrongly
classified as non-focal
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between 1.2 [22] and 1.5 [17, 19, 20], either with SUV nom-
inator and denominator values measured as mean SUV
(SUVmean) [17, 22], or as SUVmax [19, 20].
Ribeiro et al. [21] calculated the SUV ratio using the
SUVmean of the ROI divided by the SUVmean of the pancreas.
They found an average (range) SUV ratio of 1.44 (1.2–1.8) in
14 patients with focal CHI. The average value of 1.44 was
exactly the same as our optimal cut-off, but far below our
median of 1.72, and SUVmean ratios cannot be directly com-
pared to SUVmax ratios.
To the best of our knowledge, the current study is the first
blinded comparison of the visual judgment vs. an SUV ratio
cut-off in CHI patients. The test performance of the 18F–
DOPA PET/CT was identical when analyzed visually and
when the optimal SUVmax ratio cut-off was applied. Others
have advocated for a visual judgment [15, 18, 21], but only
one study reported a blinded evaluation [15]. In practice, a
combination of all available data may be helpful in the inter-
pretation of PET/CT scan results, but this will bias the assess-
ment and the diagnostic tool performance. The blinded
SUVmax ratio cut-off 1.44 should be validated in another pop-
ulation with the samemethodology [46]. Our test performance
results of 18F–DOPA PET were in line with the results of a
meta-analysis [47], which found a pooled AUC of 0.95, a
sensitivity of 0.89 (0.81–0.95) and a specificity of 0.98
(0.89–1). The meta-analysis did not differ between visual or
quantitative analysis of the PET scans or the method to obtain
SUV ratios. Kühnen et al. have in a more recent, unblinded
study found a sensitivity for predicting focal CHI of 100%
[48]. However, in 3 of their 32 patients, the extent of giant
focal lesions was severely underestimated by 18F–DOPA
PET. In our series, no giant focal lesions were present, which
is why the performance of 18F–DOPA PET vs. 68Ga-
DOTANOC PET could not be estimated for such lesions.
The combination of 18F–DOPA PET and CT (or MRI) is
an advantage for obtaining superimposed pictures of both mo-
dalities as guidance for the surgeons. We, as others [17, 19],
stress the use of diagnostic CT when a focal lesion is
suspected. In fact, one of our two failures in predicting the
location of the focal CHI lesion occurred in one of our first
patients, in whom diagnostic CT as an exception was not
performed, which is why a tail focus was impossible to discern
from kidney uptake. The other blinded localization failure by
18F–DOPA PET/CT correctly located the lesion in the
Fig. 2 ROC curves for the performance of PET/CT scans in predicting focal CHI. a 18F–DOPA PET, SUV ratio, b 68Ga-DOTANOC PET, SUVmax, c
18F–DOPA PET, SUV ratio with histology as the singular gold standard, d 68Ga-DOTANOC PET, SUVmax with histology as the singular gold standard
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pancreatic head, but failed to identify that the lesion was in
fact ectopic and situated in the duodenal wall, extending into
the pancreas. In fact, the possibility of an ectopic lesion was
raised in the nuclear medicine report, as seen after unblinding.
Focal ectopic lesions are rare and this has led to extensive
redundant pancreatic resections before the introduction of
18F–DOPA PET/CT [49, 50]. For 68Ga-DOTANOC PET/
CT, caution should be raised to not interpret labeling in an
accessory spleen as an ectopic or pancreatic tail focal lesion,
as 68Ga-DOTANOC PET shows physiological labeling in
Fig. 3 Correlation of focal SUV ratio and disease severity. a Intravenous
glucose demand, b minimal glucose value, c insulin concentration
(pmol/L), d insulin-to-glucose ratio (pmol/L: mmol/L), pro-insulin
concentration (pmol/L) and eC-peptide concentration (pmol/L). The gray
area indicates the 95% CI for the linear model
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splenic tissue in contrast to 18F–DOPA PET. No such errors
were seen in our blinded study, nor in the clinical setting.
We took the opportunity to evaluate the glucose demand
and the hyperinsulinism diagnosis during a short
hypoglycaemia after discontinuation of medication. This pro-
cedure allowed us to reveal that the glucose infusion rate off-
medication, as well as other biochemical parameters, did not
correlate with the size of the SUVmax ratio in focal CHI. This
is in keeping with a case report of a child with a high SUVmax
(no ratio given) and a visually clear focal lesion both before
and after clinical remission [51].
Not all CHI centers use time series [20–22] or general
anesthesia [19, 21, 22] for 18F–DOPA PET/CT as we did.
Our time series protocol revealed that the time of maximal
SUV varied from 10 to 60 min in 18F–DOPA and 30 to
60 min in 68Ga-DOTANOC scans, suggesting the advantage
of a time series at least in 18F–DOPA PET, where intra-
pancreatic bile duct tracing may occur. General anesthesia
was preferred in most of our patients with prolonged need
for an unmoving child.
Strengths and limitations
Strengths of our study included the blinded analysis by two
researchers with different experiences and a third blinded re-
searcher to decide any disagreements. The high kappa and
ICC values showed that the PET/CT scan estimates were ro-
bust and that knowledge of genetic and clinical details was not
mandatory for an excellent diagnostic performance.
Moreover, we used SUVmax, which is more reproducible than
SUVmean [52], and bias from a single or very few pixels was
minimized by use of an ROI shaped as a sphere. Lastly, we
used both histology and genetics as gold standards, but calcu-
lations for the histology gold standard alone did not change
the estimates.
Limitations included the retrospective nature of the study,
potential misclassification of focal vs. diffuse CHI based on
genetic results in patients not subjected to surgery, and the
earliest used dHPLC method in the genetic analysis, believed
to be of lower quality [53].
Conclusion
In conclusion, blinded 18F–DOPA PET/CT interpretation was
excellent in predicting focal CHI and localizing the lesion.
68Ga-DOTANOC PET had a lower point estimate of the
ROC AUC and superiority of 18F–DOPA PET/CTwas seen,
which is why further use of 68GA-DOTANOC PET/CT in
predicting focal CHI is discouraged.
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